Diabetes and inflammation

被引:38
作者
Cosentino, F [1 ]
Assenza, GE
机构
[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[2] Univ Roma La Sapienza, Fac Med 2, Div Cardiol, Rome, Italy
关键词
diabetes; endothelial dysfunction; inflammation; atherosclerosis;
D O I
10.1007/s00059-004-2635-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the last 50 years health care systems throughout the world have faced a new epidemic dual disease: cardiovascular disease (CVD)-diabetes mellitus. Nowadays, CVD is the leading cause of death in all western countries, and 60% of deaths for ischemic heart disease and stroke occur in developing countries with fixing resources. The striking association between CAD, stroke, peripheral artery disease and diabetes, since the publication of the first large-scale epidemiologic investigation in the 1970s, has forced physicians to investigate the possible pathophysiological connection among these diverse clinical conditions. Recent and compelling evidence has shown the significant and independent role of inflammation, insulin resistance and subsequent endothelial dysfunction in the initiation and progression of atherothrombosis, superimposed on traditional risk factors. Given the up-to-date molecular data linking diabetes, endothelial dysfunction, inflammation, and atherosclerosis, this review will focus on the common mechanisms underlying these conditions and on new promising therapeutic strategies.
引用
收藏
页码:749 / 759
页数:11
相关论文
共 101 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]   Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations [J].
Aljada, A ;
Ghanim, H ;
Mohanty, P ;
Kapur, N ;
Dandona, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) :1419-1422
[3]   Effect of insulin on human aortic endothelial nitric oxide synthase [J].
Aljada, A ;
Dandona, P .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (02) :147-150
[4]   Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation - The nonsteroidal anti-inflammatory drugs in unstable angina treatment-2 (NUT-2) pilot study [J].
Altman, R ;
Luciardi, HL ;
Muntaner, J ;
Del Rio, F ;
Berman, SG ;
Lopez, R ;
Gonzalez, C .
CIRCULATION, 2002, 106 (02) :191-195
[5]   Expression of peroxisome proliferator-activated receptor PPARδ promotes induction of PPARγ and adipocyte differentiation in 3T3C2 fibroblasts [J].
Bastie, C ;
Holst, D ;
Gaillard, D ;
Jehl-Pietri, C ;
Grimaldi, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (31) :21920-21925
[6]   Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans [J].
Beckman, JA ;
Goldfine, AB ;
Gordon, MB ;
Creager, MA .
CIRCULATION, 2001, 103 (12) :1618-1623
[7]  
BLONDIZOCCAI GGL, 2003, J AM COLL CARDIOL, V41, P1071
[8]  
Bonora E, 2000, DIABETES, V49, pA385
[9]   The diabetes epidemic: A national and global crisis [J].
Bonow, RO ;
Gheorghiade, M .
AMERICAN JOURNAL OF MEDICINE, 2004, 116 :2-10
[10]   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366